AML Follow-Up Flow Panel
Also known as: Acute Myeloid Leukemia Follow-Up Flow Panel
Use
The AML Follow-Up Flow Panel is designed to evaluate patient bone marrow and peripheral blood samples for specific cell surface and intracellular markers using flow cytometry. This test is used to follow up on existing acute myeloid leukemia (AML) cases, particularly after treatment. It helps in monitoring the patient's status and evaluating potential residual disease by characterizing leukemic cell populations.
Special Instructions
Available as global and tech-only. Providing clinical history, including time after treatment, is recommended. For pre-assessment, prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is suggested. Clinicians ordering a global or push-to-global Follow-Up Panel should provide details of the diagnosis by submitting at least one of the following: previous flow cytometry reports, previous pathology reports, and/or clinical history notes.
Limitations
Test limitations include potential variability in marker expression between samples, which can affect the interpretation of immunophenotypic patterns. Sample handling and storage must adhere strictly to specified conditions to ensure cell viability and accurate results. Differences in results may occur due to sample quality or treatment scenarios affecting cellular antigen levels.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
1-2 mL
Minimum Volume
Not provided
Container
EDTA or Sodium heparin
Collection Instructions
Please provide recent CBC report.
Storage Instructions
Refrigerate specimen. Do not freeze. Use cold pack for transport, ensuring it is not in direct contact with specimen.
Causes for Rejection
Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable.